Atypical trigeminal neuralgia (ATN) is a chronic pain condition characterized by persistent facial pain that does not respond ...

NeuroOne filed its FDA 510(k) for trigeminal nerve ablation months ahead of its revised May 2025 timeline. OneRF system targets trigeminal neuralgia, a condition impacting ~100K in the U.S., using ...

Atypical trigeminal neuralgia (ATN) is a chronic pain condition characterized by persistent facial pain that does not respond well to conventional medical treatments, often leading to significant ...

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) filed its 510(k) submission to the FDA for trigeminal nerve ablation on Wednesday, earlier than previously guided. NeuroOne Medical is ...

The anticonvulsant fosphenytoin is safe and effective in quickly decreasing pain from sudden attacks of acute trigeminal ...

“If cleared by the FDA, we believe there is a potential to generate revenues from trigeminal nerve ablation in late calendar year 2025.” NeuroOne Medical Technologies Corporation is developing ...

"If cleared by the FDA, we believe there is a potential to generate revenues from trigeminal nerve ablation in late calendar year 2025.” NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) is ...

NeuroOne Medical Technologies has submitted its 510(k) filing to the FDA for a new treatment option for trigeminal neuralgia earlier than anticipated, indicating efficient progress in product ...

(RTTNews) - NeuroOne Medical Technologies Corp. (NMTC) on Wednesday announced that it has completed its 510(k) submission to the U.S. Food and Drug Administration for its OneRF Trigeminal Nerve ...